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Abstract
Background: Increased white blood cell (WBC) count is associated with increased mortality 
in patients with ST-segment elevation myocardial infarction (STEMI). We aimed to evaluate 
predictive value of admission WBC to mean platelet volume (MPV) ratio (WMR) on prognosis 
in patients undergoing primary percutaneous coronary intervention (pPCI) for STEMI.
Methods: A total of 2,603 consecutive patients with STEMI who underwent pPCI were 
recruited for the study. Follow-up data were obtained from digital records, patient files or by 
telephone interview with patients, family members, or primary care physicians.
Results: WMR has the highest area under receiver operating characteristic (ROC) curve 
and pairwise comparisons of the ROC curves revealed that WMR has the higher discrimina-
tive ability for long-term mortality than WBC, MPV, red blood cell distribution with (RDW), 
WBC-MPV combination, and platelet to lymphocyte ratio and neutrophil to lymphocyte ratio 
(PLR-NLR) combination in patients undergoing pPCI for STEMI (a WMR value of 1,653.47 
was also found as threshold value for mortality with 75.4% sensitivity and 87.3% specificity 
by ROC curve analysis).
Conclusions: Higher WMR value on admission was associated with worse outcomes in 
patients with STEMI and independently better predicted the long-term mortality than other 
complete blood count components, such as MPV, RDW, PLR-NLR and WBC-MPV combina-
tions. (Cardiol J 2016; 23, 3: 225–235)
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Introductıon
The role of inflammation in coronary artery 
disease (CAD) has been widely recognized [1]. 
White blood cells (WBCs) and platelets have po-
tential roles in the pathogenesis of ST-segment 
elevation myocardial infarction (STEMI) [2, 3]. 
Increased WBC count is associated with increased 
mortality in patients with STEMI [4]. Mean platelet 
volume (MPV) is a potentially useful biomarker of 
platelet activity [5]. Apart from WBC count, other 
blood count parameters such as neutrophil count, 
red blood cell distribution with (RDW), mean 
platelet volume (MPV), high neutrophil to lympho-
cyte ratio (NLR) and high platelet to lymphocyte 
ratio (PLR) also seem to have prognostic value 
in STEMI [6–10]. As a combination of both WBC 
and mean platelet volume, WBC count to mean 
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platelet volume ratio (WMR) has been recently 
found as a novel non-invasive marker predict-
ing long-term outcomes in patients with non-ST 
elevation myocardial infarction (NSTEMI) [11]. 
Until now, the use of this marker for cardiovas-
cular (CV) prognosis has not been investigated in 
patients undergoing primary percutaneous coro-
nary intervention (pPCI) for STEMI. Therefore, 
we evaluated whether admission WMR obtains 
considerable prognostic information in patients 
undergoing pPCI for STEMI in a large population. 
We also assessed if this novel marker can provide 
further information in addition to other blood cell 
count parameters.
Methods
Study design
A total of 2,603 consecutive patients with 
STEMI who presented within 12 h from the onset 
of symptoms and underwent pPCI were recruited 
for the study. The study was approved by the Lo-
cal Ethics Committee and all subjects gave their 
written informed consent. Patients with active 
infection, autoimmune diseases, hematologic pro-
liferative disease, malignant neoplasia, and other 
chronic systemic disease were excluded from the 
study. Symptoms of myocardial ischemia and 
ST-segment elevation ≥ 1 mm in two contiguous 
electrocardiographic leads or new onset of complete 
left bundle-branch block were defined as ST eleva-
tion myocardial infarction. A previous diagnosis of di-
abetes mellitus (DM), use of antidiabetic medicines, 
or a fasting venous blood glucose level of 126 mg/dL 
on two occasions in previously untreated patients 
were required for a diagnosis of DM. Hyperten-
sion (HT) was defined as a previous use of antihy-
pertensive medications, a systolic pressure higher 
than 140 mm Hg, or a diastolic pressure higher than 
90 mm Hg on at least two separate measure-
ments. Hypercholesterolemia was defined as total 
cholesterol of at least 200 mg/dL. The glomerular 
filtration rate (GFR) was estimated by using the 
Modification of Diet in Renal Disease (MDRD) 
equation at admission. Left ventricular ejection 
fraction was assessed by modified biplane Simp-
son’s method in two-dimensional (2D) echocar-
diography.
Definition of re-infarction was formed accord-
ing to the Third Universal Definition of Myocardial 
Infarction [12]. Target vessel revascularization 
(TVR) was defined as the need for PCI or coronary 
surgery because of restenosis or re-occlusion of 
the infarct-related artery (IRA). Major adverse 
cardiac events (MACE) were defined as CV death, 
re-infarction, or TVR.
Coronary angiography
All pPCI procedures were performed after load-
ing dose of 300 mg acetylsalicylic acid and 300 mg 
clopidogrel by experienced interventional cardi-
ologists who were unaware of the study. Coronary 
angiography was performed using the percuta-
neous femoral route. Heparin (100 U/kg) was 
administered when the coronary anatomy was 
first assessed and the use of glycoprotein IIb/IIIa 
inhibitors was left to the preference of the op-
erator. Follow-up data were obtained from digital 
records, patient files or by telephone interview 
with patients, family members, or primary care 
physicians.
Laboratory measurements
Venous blood samples were obtained from all 
patients for hematologic and biochemical meas-
urements on admission. An automated complete 
blood count using a Coulter LH 780 Hematology 
Analyzer (Beckman Coulter Ireland Inc., Mervue, 
Galway, Ireland) was used to measure hematologic 
parameters. The PLR was calculated as the ratio 
of the platelets and lymphocytes, the NLR was 
calculated as the ratio of the neutrophils and lym-
phocytes, and WMR was calculated as the ratio of 
WBC count and MPV, all obtained from the same 
automated blood sample at admission of the study. 
The 12-h fasting serum lipid profile was measured 
by standard enzymatic methods.
Statistical analysis
Analyses were performed using SPSS Statis-
tics, version 20.0 (IBM SPSS Inc., Chicago, IL) and 
Medcalc 11.4.2 (MedCalc Software, Mariakerke, 
Belgium). Continuous variables were tested for 
normal distribution by Kolmogorov-Smirnov test 
and expressed as mean ± standard deviation or 
median (interquartile range [IQR]) values as ap-
propriate. One way ANOVA was used to compare 
data with normal distribution and the Kruskal-
Wallis H test was applied to compare the data 
without normal distribution and significance after 
Bonferroni correction for multiple comparisons. 
Categorical variables were expressed as numbers 
and percentiles and compared by c2 and Fisher’s 
exact tests. Among parameters that are found to 
be univariable and associated with the outcome, 
but also in a strong relationship with some oth-
ers; only the variables showing the strongest uni-
variable association with the outcome (p < 0.25) 
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are included in the stepwise multivariable Cox re-
gression analysis. Since there is a high correlation 
(Goodman and Kruskal’s Gamma Correlation, G = 
= 0.976, p < 0.001) which can cause multicollinearity 
between WMR risk groups and WBC-MPV combina-
tion risk groups, WMR and WBC-MPV combinations 
were included in two distinct Cox-regression models. 
Kaplan-Meier survival curves and the log-rank test 
were used to compare all-cause mortality between 
the low, intermediate, and high-risk groups. A 2-sided 
p value < 0.05 was considered statistically significant.
Results
In total, 2,603 patients, 2,129 (81.8%) males 
and 474 (18.2%) females, were recruited for the 
study. Mean age of the participants was 57.6 ± 
± 11.8. Among the participants, 625 (24.0%) 
had DM, 1,085 (41.7%) had HT and 834 (32.0%) 
had hyperlipidemia. Median follow-up time was 
12 (1–54) months.
Cutoff values for PLR, NLR, WBC, MPV and 
WMR were calculated with receiver-operating 
characteristics (ROC) curves and risk stratification 
was made according to WBC-MPV combination and 
WMR values. A PLR of 162.30 (50.8% sensitivity, 
69.9% specificity), a NLR of 6.32 (53.3% sensitivity, 
75.5% specificity), a WBC of 14,400 (57.8% sensi-
tivity, 90.3% specificity) and a MPV of 8.1 (73.2% 
sensitivity, 68.0% specificity) were found as thresh-
old values for mortality by ROC curves. If both 
PLR and NLR were above the selected threshold 
values, patients were classified as “high-risk”. If 
either PLR or NLR were above the threshold indi-
vidually, patients were classified as “intermediate-
risk”. If both levels were under threshold values, 
patients were classified as “low-risk”. In the sec-
ond model, if both WBC and MPV were above the 
selected threshold values, patients were classified 
as “high-risk”. If either WBC or MPV were above 
the threshold individually, patients were classified 
as “intermediate-risk”. If both levels were under 
threshold values, patients were classified as “low-
risk”. A WMR value of 1,653.47 was also found as 
threshold value for mortality with 75.4% sensitiv-
ity and 87.3% specificity by ROC curve analysis. 
A second ROC curve analysis was conducted for 
patients with WMR > 1,653.47 and a WMR value 
of 1,824.18 was found to show mortality with 77% 
sensitivity and 100% specificity.
Mean age and rates of female gender, DM, 
HT, anterior myocardial infarction, and cardiogenic 
shock were higher in both high-risk groups com-
pared to low and medium risk groups (Table 1).
Laboratory findings of the patients were sum-
marized in Table 2. In both high-risk groups, cre-
atinine, peak creatinine kinase-MB, glucose, RDW, 
WBC, PLR and NLR were higher and hemoglobin, 
MPV, triglyceride and GFR were lower.
Distribution of culprit vessels, number of 
diseased vessels, stent length, stent diameter 
and tirofiban use were similar among risk groups. 
However, stent use was less frequent in both 
high-risk groups compared to others. Patients with 
post-procedural Thrombolysis in Myocardial Infarc-
tion (TIMI) 3 flow were less frequent in high-risk 
groups (Table 3).
In-hospital and long-term CV events were 
shown in Table 4. Rates of in-hospital mortality, 
MACE, stroke, ventricular tachycardia-fibrillation, 
heart failure, cardiogenic shock, atrial fibrillation, 
temporary pacemaker use, gastrointestinal bleed-
ing, need for hemodialysis and blood transfusion 
were significantly higher in both high-risk groups. 
Rate of in-hospital re-infarction was higher in WMR 
high-risk group but did not differ between WBC- 
-MPV combination risk groups. Rates of long-term 
CV mortality, MACE, heart failure and re-infarction 
was significantly higher in both high risk groups 
compared to low and intermediate-risk groups. 
However, long-term stroke and TVR rates were 
similar among the groups.
Age > 70, male gender, HT, DM, Killip class 
> 1, heart rate > 100 bpm, admission anemia, 
RDW and PLR-NLR combination were found as 
independent predictors of long-term CV mortal-
ity in Cox regression models I and II. In addition, 
WBC-MPV combination was an independent pre-
dictor of mortality in model I and WBC/PLR was 
an independent predictor of mortality in model II. 
Strongest predictors of mortality were WBC-MPV 
combination high-risk group in model I and WMR 
high-risk group in model II. Since the –2 Log Likeli-
hood (LL) value was lower in model II than model I 
(model I: –2 LL = 2,675.6, c2 = 635.7, p < 0.001; 
model II: 2 LL = 2,564.8, c2 = 811.5, p < 0.001), 
model II was found more appropriate for mortality 
prediction (Table 5).
Receiver operating characteristic curves of 
WBC-MPV combination, WMR, PLR-NLR combi-
nation and their components for long-term mortal-
ity is shown in Figure 1. WMR has the highest area 
under ROC curve and pairwise comparisons of the 
ROC curves revealed that WMR has the highest dis-
criminative ability for long-term mortality (Fig. 1). 
A log-rank p value < 0.001 was obtained while 
comparing survival amongst three risk groups in 
both risk models (Fig. 2).
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Discussion
In this study, we have demonstrated for the 
first time that elevated admission WMR was as-
sociated with MACE and worse outcomes during 
in-hospital and long-term follow-up in patients with 
STEMI. Age, male gender, HT, anemia, RDW, PLR-
NLR combination, WBC-MPV combination and 
WMR were the independent predictors of mortality 
in patients with STEMI. Moreover, higher WMR 
was associated with a significant increase in the 
risk of MACE incidence, and it was a stronger 
marker than MPV, RDW, PLR-NLR and WBC-MPV 
combinations in prediction of the in-hospital and 
long-term clinical outcomes.
Previous studies showed that some basic 
hematologic parameters such as MPV, RDW, NLR 
and PLR may have a role in predicting worse out-
comes in patients with STEMI undergoing pPCI 
[7, 13–15]. As a constituent of the link between 
inflammation, thrombosis, and atherogenesis, 
platelets have a prominent role in progression 
of atherosclerosis and an increase in the platelet 
count can show advanced thrombocyte activation 
and megakaryocytic augmentation. Platelet surface 
molecules are essential in the interaction with 
endothelial cells, leukocytes and matrix molecules 
affecting atherogenesis. Platelets play an active 
role in platelet-fibrin formation and development 
of acute myocardial infarction. Several studies have 
showed that higher platelet count and lymphopenia 
were related with poor clinical outcomes in vari-
ous cardiovascular diseases [10, 13]. Azab et al. 
[16] showed that increased PLR is an independ-
ent predictor of long-term mortality in patients 
with NSTEMI. MPV is a useful marker of platelet 
activity. Several studies showed close relation-
ship between MPV levels and worse outcomes 
in patients with acute coronary syndromes (ACS) 
[8, 17]. Bigger platelets made from activated mega-
Table 1. Baseline characteristics of the patients.
Variables Combined WBC-MPV P WMR P
Low risk  
(n = 1,209)
Intermediate 
risk  
(n = 1,266)
High risk  
(n = 128)
Low risk  
(n = 2,120)
Intermediate 
risk  
(n = 340)
High risk  
(n = 143)
Age [years] 57.5 ± 11.4 57.2 ± 12 62.3 ± 12†‡ < 0.001* 57.6 ± 11.7 55.1 ± 11.7 63.9 ± 11.8†‡ < 0.001*
Male gender 978 (80.9) 1062 (83.9) 89 (69.5) 0.001* 1738 (82) 292 (85.9) 99(69.2) < 0.001*
Smoking 730 (60.4) 757 (59.8) 70 (54.7) 0.458 1251 (59) 233 (68.5) 73 (51) < 0.001*
Diabetes 294 (24.3) 274 (21.6) 57 (44.5) < 0.001* 486 (22.9) 71 (20.9) 68 (47.6) < 0.001*
Hypertension 507 (41.9) 511 (40.4) 67 (52.3) 0.033* 875 (41.3) 136 (40) 74 (51.7) 0.039*
Family history 237 (19.6) 258 (20.4) 12 (9.4) 0.007* 416 (19.6) 78 (22.9) 13 (9.1) 0.001*
Hyperlipidemia 393 (32.5) 410 (32.4) 31 (24.2) 0.147 693 (32.7) 109 (32.1) 32 (22.4) 0.138
Dialysis 0 (0) 4 (0.3) 1 (0.8) 0.082 2 (0.1) 2 (0.6) 1 (0.7) 0.065
Prior CABG 45 (3.7) 32 (2.5) 5 (3.9) 0.178 74 (3.5) 3 (0.9) 5 (3.5) 0.018*
PCI history 107 (8.9) 109 (8.6) 19 (14.8) 0.042* 181 (8.5) 29 (8.5) 25 (17.5) 0.003*
Prior MI 152 (12.6) 129 (10.2) 24 (18.8) 0.008* 241 (11.4) 32 (9.4) 32 (22.4) 0.001*
Anterior MI 527 (43.6) 608 (48) 75 (58.6) 0.002* 937 (44.2) 189 (55.6) 84 (58.7) < 0.001*
Admission CS 15 (1.2) 32 (2.5) 30 (23.4) < 0.001* 29 (1.4) 15 (4.4) 33 (23.1) < 0.001*
Angina-to-perfusion time [h] 4 ± 118 4 ± 58 4.5 ± 10 0.462 4 ± 88 3.5 ± 58 4 ± 8 0.977
Killip class > 1 47 (3.9) 60 (4.7) 50 (39.1) < 0.001* 74 (3.5) 29 (8.5) 54 (37.8) < 0.001*
SBP < 100 mm Hg 89 (7.4) 102 (8.1) 44 (34.4) < 0.001* 149 (7) 34 (10) 52 (36.4) < 0.001*
Heart rate > 100 bpm 34 (2.8) 52 (4.1) 37 (28.9) < 0.001* 56 (2.6) 26 (7.6) 41 (28.7) < 0.001*
Admission anemia 289 (23.9) 316 (25) 43 (33.6) 0.055 522 (24.6) 70 (20.6) 56 (39.2) < 0.001*
LVEF [%] 48.2 ± 7.8 47.3 ± 7.8 41 ± 11.3†‡ < 0.001* 48.1 ± 7.6 46.5 ± 8.8 40.5 ± 11.3†‡ < 0.001*
Time of hospital stay [days] 6 (3) 6 (3) 7 (8) 0.374 6 (3) 6 (3) 7 (8) 0.326
Follow-up period [months] 9 (22) 18 (28)† 2 (9.8)†‡ < 0.001* 13 (25) 14 (28) 1 (9)†‡ < 0.001*
Continues variables are reported mean ± standard deviation or median (interquarticle range). Categorical variables are reported n (%).*p < 0.05 
was considered significant;†p < 0.05 vs. low risk (Bonferroni correction); ‡p < 0.05 vs. intermediate risk (Bonferroni correction); CABG — coro- 
nary artery bypass grafting; CS — cardiogenic shock; LVEF — left ventricular ejection fraction; MI — myocardial infarction; SBP — systolic 
blood pressure; PCI — percutaneous coronary intervention; WBC-MPV — white blood cell-mean platelet volume; WMR — white blood cell 
count to mean platelet volume ratio
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Table 4. In-hospital and long-term cardiac events.
Event Combined WBC-MPV P WMR P
Low risk  
(n = 1,209)
Intermediate 
risk  
(n = 1,266)
High risk 
(n = 128)
Low risk 
(n = 2,120)
Intermediate 
risk  
(n = 340)
High risk 
(n = 143)
In-hospital event and complications:
In-hospital mortality 10 (0.8) 37 (2.9) 55 (43) < 0.001* 24 (1.1) 14 (4.1) 64 (44.8) < 0.001*
Reinfarction 25 (2.1) 26 (2.1) 6 (4.7) 0.153 39 (1.8) 12 (3.5) 6 (4.2) 0.031*
TVR 52 (4.3) 49 (3.9) 9 (7) 0.214 84 (4) 15 (4.4) 11 (7.7) 0.112
MACE 59 (4.9) 83 (6.6) 60 (46.9) < 0.001* 104 (4.9) 29 (8.5) 69 (48.3) < 0.001*
Stroke 1 (0.1) 10 (0.8) 5 (3.9) < 0.001* 6 (0.3) 4 (1.2) 6 (4.2) < 0.001*
CPR 22 (1.8) 45 (3.6) 56 (43.8) < 0.001* 40 (1.9) 18 (5.3) 65 (45.5) <0.001*
Hemodialysis 6 (0.5) 8 (0.6) 7 (5.5) < 0.001* 10 (0.5) 3 (0.9) 8 (5.6) < 0.001*
VT/VF 42 (3.5) 56 (4.4) 39 (30.5) < 0.001* 72 (3.4) 22 (6.5) 43 (30.1) < 0.001*
Heart failure 85 (7) 139 (11) 64 (50.0) < 0.001* 172 (8.1) 47 (13.8) 69 (48.3) < 0.001*
Requaring inotrope 47 (3.9) 89 (7) 67 (52.3) < 0.001* 99 (4.7) 29 (8.5) 75 (52.4) < 0.001*
Cardiogenic shock  
and IABP
18 (1.5) 37 (2.9) 48 (37.5) < 0.001* 34 (1.6) 17 (5) 52 (36.4) < 0.001*
Atrial fibrillation 20 (1.7) 20 (1.6) 7 (5.5) 0.019* 32 (1.5) 7 (2.1) 8 (5.6) 0.007*
Complete AVB 39 (3.2) 37 (2.9) 20 (15.6) < 0.001* 67 (3.2) 10 (2.9) 19 (13.3) < 0.001*
Transient pacemaker 41 (3.4) 26 (2.1) 23 (18.0) < 0.001* 59 (2.8) 8 (2.4) 23 (16.1) < 0.001*
GI bleeding 7 (0.6) 14 (1.1) 5 (3.9) 0.008* 15 (0.7) 6 (1.8) 5 (3.5) 0.004*
Access site complication 56 (4.6) 47 (3.7) 7 (5.5) 0.367 87 (4.1) 17 (5) 6 (4.2) 0.775
Acute stent thrombosis 16 (1.3) 12 (0.9) 3 (2.3) 0.229 26 (1.2) 2 (0.6) 3 (2.1) 0.329
Blood transfusion 39 (3.2) 39 (3.1) 13 (10.2) 0.001* 61 (2.9) 17 (5) 13 (9.1) < 0.001*
Long-term cardiac events:
Cardiovascular mortality 14 (1.2) 81 (6.4) 68 (53.1) < 0.001* 42 (2) 29 (8.5) 92 (64.3) < 0.001*
Heart failure 58 (4.8) 79 (6.2) 27 (21.1) < 0.001* 106 (5) 24 (7.1) 34 (23.8) < 0.001*
Stroke 12 (1) 15 (1.2) 2 (1.6) 0.693 24 (1.1) 1 (0.3) 4 (2.8) 0.068
Reinfarction 50 (4.1) 90 (7.1) 14 (10.9) 0.001* 108 (5.1) 26 (7.6) 20 (14) < 0.001*
TVR 171 (14.1) 207 (16.4) 14 (10.9) 0.126 311 (14.7) 64 (18.8) 17 (11.9) 0.076
MACE 204 (16.9) 293 (23.1) 68 (53.1) < 0.001* 383 (18.1) 92 (27.1) 90 (62.9) < 0.001*
*p < 0.05 was considered significant; Mean values (standard deviation [SD]) and n (%) are reported for continuous and categorical variables, 
respectively; AVB — atrioventricular block; CPR — cardiopulmonary resuscitation; GI — gastrointestinal; IABP — intra-aortic balloon pump; 
MACE — major adverse cardiovascular event (cardiovascular death, reinfarction, TVR); TVR — target vessel revascularization; VT/VF — ventricu-
lar tachycardia/fibrillation; WBC-MPV — white blood cell-mean platelet volume; WMR — white blood cell count to mean platelet volume ratio
karyocytes are more sensitive than normal size 
platelets. Larger platelets are likely to be available 
well before the acute coronary artery occlusion 
responsible for ACS. For this reason, it is reason-
able that hyperactive and larger platelets constitute 
a significant determinant of the thrombogenic 
process underlying the total occlusion of the 
coronary artery leading to STEMI. Several stud-
ies have suggested that MPV could be a marker 
of coronary perfusion in STEMI patients. Huczek 
et al. [18] showed MPV to be an independent pre-
dictor for the no-reflow phenomenon after pPCI. 
Estévez-Loureiro et al. [15] found that increased 
MPV is an independent predictor of both a patent 
IRA and 30-day mortality in patients with STEMI 
undergoing pPCI. RDW is a marker of variation 
in the size of circulating red cells (anisocytosis), 
and increased RDW levels can be considered the 
production of humoral mediators by the bone mar-
row. Inflammatory cytokines and neurohumoral 
mediators are activated in the process of STEMI. 
Elevated RDW was an independent predictor of 
mortality and morbidity in patients with heart 
disease. Tonelli et al. [19] found an independent 
relation between higher RDW levels and the risk 
of death and CV events in patients with CAD. 
Activated neutrophils release several proteolytic 
enzymes which increase the tissue destruction, 
such as acid phosphatase, myeloperoxidase, and 
elastase [20–22]. Activation of the neurohormonal 
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Table 5. Cox-regression models revealing independent predictors of long-term cardiovascular mortality 
in all study patients.
Variables Model I Model II
HR (95% CI) P HR (95% CI) P
Age ≥ 70 [years] 1.726 (1.298–2.294) < 0.001* 1.800 (1.354–2.393) < 0.001*
Male gender 0.725 (0.534–0.984) 0.039* 0.597 (0.454–0.784) 0.001*
Hypertension 1.336 (1.005–1.775) 0.046* 1.427 (1.086–1.876) 0.011*
Diabetes mellitus 1.440 (1.061–1.955) 0.019* 1.432 (1.052–1.949) 0.022*
Killip class > 1 2.166 (1.478–3.174) < 0.001* 2.043 (1.395–2.991) < 0.001*
Heart rate > 100 bpm 2.646 (1.714–4.085) < 0.001* 2.349 (1.539–3.584) < 0.001*
Admission anemia 1.407 (1.064–1.862) 0.017* 1.452 (1.101–1.915) 0.008*
RDW 1.097 (1.016–1.183) 0.018* 1.213 (1.138–1.291) 0.001*
PLR-NLR combination:
Low risk (PLR £ 162.0 and NLR £ 6.32) Reference Reference
Intermediate risk (PLR > 162.1 or NLR > 6.32) 1.423 (0.977–2.072) 0.066 1.269 (0.866–1.860) 0.222
High risk (PLR > 162.0 and NLR > 6.32) 1.821 (1.328–2.496) < 0.001* 1.672 (1.212–2.305) 0.002*
WBC-MPV combination:
Low risk (WBC £ 14,400 and MPV > 8.1) Reference – –
Intermediate risk (WBC > 14,400 or MPV £ 8.1) 2.441 (1.529–3.895) < 0.001* – –
High risk (WBC > 14,400 and MPV £ 8.1) 5.375 (3.230–8.947) < 0.001* – –
WMR:
Low risk (WMR £ 1,653.47) – – Reference
Intermediate risk (1,653.47 < WMR £ 1,824.18) – – 2.639 (1.752–3.975) < 0.001*
High risk (WMR > 1,824.18) – – 7.075 (4.869–10.280) < 0.001*
Omnibus tests of model coefficients –2 LL = 2,675.6,  
c2 = 635.7, p < 0.001
–2 LL = 2,564.8,  
c2 = 811.5, p < 0.001
*p < 0.05 was considered significant;  CI — confidence interval; HR — hazard ratio; LL — Log Likelihhood; NLR — neutrophil–lymphocyte ra-
tio; MPV — mean platelet volume; PLR — platelet-lymphocyte ratio; RDW — red blood cell distribution with; WBC — white blood cell;  
WMR — white blood cell count to mean platelet volume ratio
system, oxidative stress and inflammation in ACS 
increase the catecholamine levels and the plasma 
cortisol levels cause bone marrow suppression and 
down-regulation of the lymphocyte proliferation 
and differentiation with aggravated lymphocyte 
apoptosis. In a recent study, He et al. [23] showed 
that average NLR was a useful and powerful predic-
tor of mortality and adverse-outcomes in Chinese 
patients presenting with STEMI. Elevated leuko-
cytes are associated with increased mortality in 
patients with myocardial infarction [24]. Several 
mechanisms can explain this relationship; 1) leu-
kocytes can cause injury of endothelial cells by 
oxidative and proteolytic damage, 2) leukocytes 
can plug the microvascularization, 3) leukocytes 
can stimulate hypercoagulability and activated 
monocytes [25]. In a recent study, Dharma et al. 
[25] reported that high blood leukocyte count on ad-
mission was an independent predictor of CV events 
in patients with NSTEMI. Furthermore, Sabatine 
et al. [26] found that an elevated baseline WBC 
count correlated with impaired myocardial perfu-
sion and increased 6-month mortality in patients 
with STEMI. Maden et al. [27] showed that higher 
WBC and MPV is associated with occluded IRA in 
patients with STEMI. Karahan et al. [28] observed 
that increased WBC and MPV are independent 
predictors of impaired microvascular perfusion in 
patients with STEMI. Increased WBCs may appear 
as a significant factor showing impaired microvas-
cular reperfusion. Recently, Dehghani et al. [11] 
investigated a novel parameter called WMR as 
a marker predicting long-term outcomes in patients 
with NSTEMI. They suggested that WMR is a bet-
ter predictor of worse outcomes in patients with 
NSTEMI than WBC and MPV [11]. In light of these 
evidences, we decided to evaluate the prognostic 
value of WMR with a large number of patients with 
STEMI undergoing pPCI and demonstrated that 
WMR is a better indicator of predicting the poor 
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Figure 2. Kaplan-Meier cumulative survival curves for patients with mortality according to combined white blood 
cell (WBC) (A)-mean platelet volume (MPV) and white blood cell count to mean platelet volume ratio (WMR) (B) risk 
stratification.
Pairwise comparison of ROC curves
WMR ~ MPV
Difference between areas 0.0998
Standard errorc 0.0183
95% confidence interval 0.0639 to 0.136
z statistic 5.451
Significance level p < 0.0001
WMR ~ WBC
Difference between areas 0.0526
Standard errorc 0.00665
95% confidence interval 0.0369 to 0.0657
z statistic 7.913
Significance level p < 0.0001
WMR ~ WBC-MPV combination
Difference between areas 0.0396
Standard errorc 0.0114
95% confidence interval 0.0172 to 0.0619
z statistic 3.471
Significance level p = 0.0005
WMR ~ PLR-NLR combination
Difference between areas 0.208
Standard errorc 0.0223
95% confidence interval 0.164 to 0.251
z statistic 9.308
Significance level p < 0.0001
WMR ~ RDW
Difference between areas 0.222
Standard errorc 0.0249
95% confidence interval 0.174 to 0.271
z statistic 8.936
Significance level p < 0.0001
cDeLong et al. 1988
AUC SEa 95% CIb
MPV 0.756 0.0161 0.739 to 0.773
WBC 0.803 0.0178 0.788 to 0.819
WMR 0.856 0.0166 0.842 to 0.869
WBC-MPV combination 0.817 0.0142 0.801 to 0.831
PLR-NLR combination 0.649 0.0175 0.630 to 0.667
RDW 0.634 0.0188 0.615 to 0.652
aDeLong et al. 1988
bBinomia I exact
Figure 1. Receiver operating characteristic curves identifying the discrimination thresholds of white blood cell (WBC)-
-mean platelet volume (MPV) combination, white blood cell count to mean platelet volume ratio (WMR), platelet to 
lymphocyte ratio and neutrophil to lymphocyte ratio (PLR-NLR) combination and their components for long-term 
mortality; RDW — red blood cell distribution with.
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outcomes in STEMI than MPV, RDW, PLR-NLR 
and WBC-MPV combinations.
White blood cell count to mean platelet volume 
ratio has some key properties that a novel CV prog-
nostic marker should have [29, 30]. First, WMR 
is obtained easily from routine complete blood 
counts without additional work or cost. Second, it 
provides information about hard endpoints such as 
in-hospital an long-term mortality. Moreover, it is 
also useful for risk stratification in patients classi-
fied into risk groups according to WMR levels. Such 
risk stratification may allow clinicians to determine 
patients who are at higher risk and individualizing 
the therapy. In patients with elevated WMR, more 
intensive medical therapy and more aggressive 
control of CV risk factors may be considered. In this 
high-risk population, more close follow-up visits 
can also be arranged. However, further studies 
with long-term follow-up and large-scale prospec-
tive data are needed to elucidate the exact role of 
WMR in patients with CAD.
Limitations of the study
Our study findings should be interpreted with 
some limitations. First, it was a single-center, 
retrospective study without randomization. In-
flammatory markers, such as high-sensitivity 
C-reactive protein, B-type natriuretic peptide, 
other pro-inflammatory cytokines, and markers 
of oxidative stress were not analyzed. Using 
a spot laboratory value of complete blood counts 
rather than values at a time-interval is another 
limitation of this study.
Conclusions
In conclusion, higher WMR value on admission 
was associated with worse outcomes in patients 
with STEMI and independently predicted the long-
term mortality better than other complete blood 
count components, such as MPV, RDW, PLR-NLR 
and WBC-MPV combinations.
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